 |
|
|
| |
CABOTEGRAVIR + RILPIVIRINE LONG-ACTING
AS HIV-1 MAINTENANCE THERAPY: ATLAS WEEK 96 RESULTS
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Susan Swindells,1 Thomas Lutz,2 Lelanie Van Zyl,3 Norma Porteiro,4 Paul Benn,5 Jenny O. Huang,6 Conn M. Harrington,7 Kai Hove,8
Susan L. Ford,6 Christine L. Talarico,7 Vasiliki Chounta,5 Herta Crauwels,9 Rodica Van Solingen-Ristea,9 Simon Vanveggel,9
David A. Margolis,7 Kimberly Y. Smith,7 Kati Vandermeulen,9 William R. Spreen7
1University of Nebraska Medical Center, Omaha, NE, USA; 2Infektiologikum, Frankfurt, Germany; 3Syzygy Clinical Research Services, Pretoria, South Africa;
4Fundación IDEAA, Buenos Aires, Argentina; 5ViiV Healthcare, Brentford, UK; 6GlaxoSmithKline, Research Triangle Park, NC, USA; 7ViiV Healthcare,
Research Triangle Park, NC, USA; 8GlaxoSmithKline, London, UK; 9Janssen Research and Development, Beerse, Belgium Presenting author: Susan Swindells; sswindells@unmc.edu
|
| |
|
|
|
|
|
